Research Trends in Immune Checkpoint Blockade for Melanoma: Visualization and Bibliometric Analysis

Research Trends in Immune Checkpoint Blockade for Melanoma: Visualization and Bibliometric Analysis

BACKGROUND: Melanoma is one of the most life-threatening skin cancers; immune checkpoint blockade is widely used in the treatment of melanoma because of its remarkable efficacy. OBJECTIVE: This study aimed to conduct a comprehensive bibliometric analysis of research conducted in recent decades on im...

Full description

Bibliographic Details
Main Authors:	Chen, X. (Author), Jiang, Z. (Author), Kuang, X. (Author), Liu, H. (Author), Xu, Y. (Author)
Format:	Article
Language:	English
Published:	NLM (Medline) 2022
Subjects:	bibliometric bibliometrics Bibliometrics cancer dermatology human Humans immune checkpoint blockade Immune Checkpoint Inhibitors melanoma Melanoma research trends United States
Online Access:	View Fulltext in Publisher

Similar Items

Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
by: Yiting Sun, et al.
Published: (2021-08-01)

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade
by: Elizabeth I. Buchbinder, et al.
Published: (2021-04-01)

Smoldering myocarditis following immune checkpoint blockade
by: Timothy G. Norwood, et al.
Published: (2017-11-01)

Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators
by: Hwa Kyung Byun, et al.
Published: (2021-05-01)

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
by: Markus V. Heppt, et al.
Published: (2019-11-01)

Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade
by: Thilo Gambichler, et al.
Published: (2017-05-01)

Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors
by: Sonja C. S. Simon, et al.
Published: (2020-01-01)

The age of enlightenment in melanoma immunotherapy
by: Mark R. Albertini
Published: (2018-08-01)

Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports
by: Stefan Schliep, et al.
Published: (2018-01-01)

Enhanced Antitumor Response to Immune Checkpoint Blockade Exerted by Cisplatin-Induced Mutagenesis in a Murine Melanoma Model
by: Falih M. Gorgun, et al.
Published: (2021-07-01)

Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
by: Magdalena Olbryt, et al.
Published: (2020-06-01)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
by: Teresa Kim, et al.
Published: (2014-12-01)

Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
by: Nicholas D. Klemen, et al.
Published: (2019-07-01)

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
by: Andrew Hantel, et al.
Published: (2018-07-01)

Research Interest and Public Interest in Melanoma: A Bibliometric and Google Trends Analysis
by: Hanlin Zhang, et al.
Published: (2021-02-01)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
by: Anja Wessely, et al.
Published: (2020-01-01)

The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis
by: Li P, et al.
Published: (2018-10-01)

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
by: Markus V. Heppt, et al.
Published: (2017-08-01)

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis
by: Elias A. T. Koch, et al.
Published: (2021-07-01)

Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients
by: Devayani Machiraju, et al.
Published: (2021-01-01)

Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan
by: Chiao-En Wu, et al.
Published: (2020-06-01)

Systematic diagnostic evaluation for immune-related colitis: a single institutional review of advanced melanoma patients treated with ipilimumab
by: Garcia-Neuer, Marlene
Published: (2016)

MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors
by: Maria Letizia Motti, et al.
Published: (2020-06-01)

The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients
by: Katarzyna Tomela, et al.
Published: (2020-09-01)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
by: Vera Petrova, et al.
Published: (2020-03-01)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
by: Kalijn Fredrike Bol, et al.
Published: (2019-10-01)

Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report
by: Anne Fröhlich, et al.
Published: (2020-05-01)

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma
by: Junjie Jiang, et al.
Published: (2020-11-01)

Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors
by: Jesper Geert Pedersen, et al.
Published: (2020-05-01)

Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients
by: Kaat de Jonge, et al.
Published: (2021-01-01)

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
by: Jan-Malte Placke, et al.
Published: (2021-09-01)

Overcoming Immune Evasion in Melanoma
by: Kevinn Eddy, et al.
Published: (2020-11-01)

Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series
by: Abdul Rafeh Naqash, et al.
Published: (2019-01-01)

Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade
by: Rachel L. Y. Ho, et al.
Published: (2021-07-01)

Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma
by: Weiyin Lin, et al.
Published: (2020-11-01)

PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates
by: Yago Pico de Coaña, et al.
Published: (2020-01-01)

Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis
by: Maen Abdelrahim, et al.
Published: (2021-01-01)

Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma
by: Catherine A. Gao, et al.
Published: (2019-10-01)

Current Status and Prospects of Immunotherapy for Gynecologic Melanoma
by: Mayuka Anko, et al.
Published: (2021-05-01)

Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma
by: Angela Rita Elia, et al.
Published: (2018-07-01)

Cannot write session to /tmp/vufind_sessions/sess_5qtd9ngtlda3rpusnsnnjt3aat